Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.

A highly significant reduction ( p < 0.001) in the Cmin for dalbavancin and in the corresponding pharmacokinetic variability was observed in the following injections: 60%, 50%, 57%, 42%, and 51% from the third to more than six injections ( Figure 1 ).

also in 132,142 other papers